News from wuxi apptec A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Dec 02, 2020, 19:00 ET WuXi AppTec Recognized by Frost & Sullivan with 2020 Global Customer Value Leadership Award

WuXi AppTec, a leading global provider of R&D and manufacturing enabling services in the pharmaceutical, biotechnology and medical device industries, ...

Dec 01, 2020, 08:00 ET ViGeneron and WuXi Advanced Therapies Enter Strategic Manufacturing Partnership for Next-Generation Ophthalmic Gene Therapy

ViGeneron, a gene therapy company, and WuXi Advanced Therapies Inc. (WuXi ATU), a leading Contract, Testing, Development and Manufacturing...

Nov 18, 2020, 08:00 ET WuXi Advanced Therapies Expands Philadelphia Campus with New State-of-The-Art Testing Laboratory

WuXi Advanced Therapies Inc. (WuXi ATU) – a business unit of WuXi AppTec offering end-to-end contract services for the cell and gene therapies...

Nov 12, 2020, 08:00 ET WuXi Advanced Therapies Expands Services to Include High-Quality and Cost-Effective R&D and GMP Plasmid DNA

WuXi Advanced Therapies Inc. (WuXi ATU) today announced the expansion of its Cell & Gene Therapy Platforms with capabilities to provide high-quality...

Oct 29, 2020, 04:27 ET WuXi AppTec Reports Strong Third-Quarter 2020 Results

Revenue Growth Accelerated to 35.4% Year-Over-Year to RMB 4,583 Million Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 44.3%...

Aug 13, 2020, 04:49 ET WuXi AppTec Achieved Strong Growth in First-Half of 2020 with China Sites Resuming Full Operations

WuXi AppTec Second-Quarter 2020 Results Revenue Up 29.4% YoY to RMB4,044 Million Net Profit Attributable to Owners of the Company Up 111.0% YoY to...

Jul 09, 2020, 04:32 ET WuXi AppTec to Launch a Special Webinar on Collaborations that Transform on July 16 | Advances in Rare Diseases: Hemophilia

WuXi AppTec is pleased to announce that they are about to launch the second session of the webinar series "Collaborations That Transform,"...

Jun 01, 2020, 08:00 ET WuXi AppTec Appoints Dr. David Chang as CEO of WuXi Advanced Therapies Business Unit

WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, announced today the...

May 18, 2020, 09:00 ET WuXi Advanced Therapies Launches New Closed Process CAR-T Cell Therapy Platform

WuXi Advanced Therapies, a leading global Contract Development and Manufacturing Organization (CDMO) offering end-to-end contract services for the...

Apr 29, 2020, 05:30 ET WuXi AppTec Reports Solid First-Quarter 2020 Results

WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable...

Mar 24, 2020, 06:56 ET WuXi AppTec Reports Strong 2019 Annual Results

WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable...

Mar 11, 2020, 08:00 ET WuXi AppTec Wuhan Site Resumes Operation

WuXi AppTec announced today that the company's Wuhan site has resumed operations, in compliance with local regulations and global COVID-19 health and ...

Feb 12, 2020, 07:00 ET WuXi AppTec China Sites Resume Operations after Extended Lunar New Year Holiday

With the end of the extended Lunar New Year holiday, WuXi AppTec sites in China have resumed operations today, with the exception of our site in...

Jan 13, 2020, 09:00 ET WuXi Advanced Therapies Launches New World-Class AAV Vector Suspension Platform

WuXi Advanced Therapies, a leading global Contract Development and Manufacturing Organization (CDMO) offering end-to-end contract services for the...

Jan 02, 2020, 19:10 ET WuXi STA Opens Oligonucleotide Large-Scale Manufacturing Facility

STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – today announced the opening of its large-scale oligonucleotide active...

Nov 28, 2019, 19:00 ET WuXi ATU and GeneMedicine Sign Development and Manufacturing Agreement for Oncolytic Virus Products

WuXi ATU Co., Ltd., (WuXi ATU) - a subsidiary of WuXi AppTec, and GeneMedicine - a South Korea-based gene therapy biotechnology company, have formed...

Nov 17, 2019, 19:00 ET WuXi AppTec's Lab Testing Division Expands Toxicology Facility in Suzhou, China

WuXi AppTec, a leading global provider of R&D and manufacturing services enabling companies in the pharmaceutical, biotechnology and medical device...

Nov 14, 2019, 19:00 ET WuXi AppTec Receives 2019 Global Integrated Drug Development Competitive Strategy Innovation & Leadership Award from Frost & Sullivan

WuXi AppTec, a leading global provider of R&D and manufacturing services enabling companies in the pharmaceutical, biotechnology and medical device...

Nov 10, 2019, 19:00 ET Dr. Ge Li Awarded "CEO of the Year" at CPhI Worldwide 2019

WuXi AppTec, a leading global provider of R&D and manufacturing services enabling companies in the pharmaceutical, biotechnology and medical device...

Nov 06, 2019, 03:00 ET WuXi AppTec Receives Investment Grade Corporate Ratings from Three Global Rating Agencies

WuXi AppTec announced today that it has received investment grade corporate credit ratings from three global rating agencies: Moody's (Baa3), S&P...

Oct 30, 2019, 08:03 ET WuXi AppTec Reports Third-Quarter 2019 Results

WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable...

Oct 27, 2019, 20:00 ET WuXi STA's Jinshan Facility Passes EMA Inspection

STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – announced today that its Jinshan manufacturing facility in Shanghai, China...

Oct 10, 2019, 20:02 ET WuXi AppTec Research Service Division and BioSolveIT Introduce GalaXi®, a Vast New Chemical Space of Tangible Molecules

WuXi AppTec Research Service Division and BioSolveIT today launched a new virtual chemical space called GalaXi®. Largely built from WuXi AppTec's...

Sep 03, 2019, 20:00 ET WuXi AppTec Launches DNA Encoded Library (DEL) Service Package "DELight" to Expedite Early Drug Discovery

WuXi AppTec today announced its launch of DELight, a novel DNA Encoded Library (DEL) service package, providing cost-effective and efficient hit...

Aug 19, 2019, 07:20 ET WuXi AppTec Reports First Half 2019 Interim Results

WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a platform that provides a broad portfolio of R&D and manufacturing services that enable...